Saturday, November 18, 2017
EATG, News

Zepatier accepted for routine use in Scotland

January 17, 2017

On January 16 the Scottish Medicines Consortium (SMC) published advice accepting Zepatier for routine use in NHS Scotland.

Elbasvir-grazoprevir (Zepatier) was accepted for the treatment of chronic hepatitis C. Elbasvir-grazoprevir is a combination of two medicines that inhibit the replication of the hepatitis C virus and offers the prospect of a cure for hepatitis C infection.

“Eradicating hepatitis C is a key commitment for Scottish Government and new medicines for this condition will help achieve this aim.” (Professor Jonathan Fox, chairman of the SMC)